—
C+
C+ The full Closelook — membership. Open the C+ overview

Argen-X (ARGX.BR) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Argen-X

ARGX.BR in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Argen-X develops antibody therapies for autoimmune disease, selling VYVGART and VYVGART HYTRULO for conditions such as myasthenia gravis and CIDP. Its pipeline extends the same FcRn-blocking approach into other immune disorders and adds candidates aimed at inflammation and antibody-driven disease. It works with partners including Zai Lab, Halozyme and AbbVie to develop or commercialise specific molecules. The company is based in Amsterdam and listed in Brussels.
Where it sits in the stack
Argen-X carries no seat in Rubin, our AI build-out index, and sits instead in the Healthcare sector of the wider Closelook universe, where it is grouped with other scored biopharma names rather than tied to any hardware or software layer.
Who it is priced against
Closelook's peer group places it with other scored healthcare names — Eli Lilly, Regeneron, BeiGene, UCB and Medpace among them — reflecting shared sector rather than shared disease area; the market also names Argenx's ADR line as the same company traded in New York.
Why Closelook tracks it
It carries a Closelook score with momentum as the strongest module and valuation as the weakest; it holds no seat in Rubin or our other indices and has not drawn quotes in the diary's editions.
What the diary watches
Whether commercial uptake of VYVGART across its approved uses keeps momentum ahead of a valuation module that the score already marks as the weak point.

Argen-X (ARGX.BR) trades on the BR exchange in Belgium, classified under Healthcare.

The Closelook company score reads 65/100 composite (momentum 79, quality 75, valuation 28) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ARGX.BR, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · 8 names with week and year-to-date

Peer group

Biotechnology

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ARGX.BR on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What ARGX.BR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +1.3% in FY2025 248 m EUR of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in Europe: +3.0% week · −4.5% month · −2.1% quarter · −5.0% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Argen-X (ARGX.BR)?

Argen-X trades as ARGX.BR on the BR exchange (Belgium) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is ARGX.BR in a Closelook index?

Not currently — Argen-X is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Argen-X's Closelook composite score?

65 out of 100, with momentum 79, quality 75 and valuation 28 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ARGX.BR trade against its moving averages?

Uptrend stack intact: Trades +6.6% vs the 50-day and +19% vs the 200-day average, 5.8% below the 52-week high and +53.3% off the 52-week low; a golden cross printed 72 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Argen-X do?

Argen-X develops antibody therapies for autoimmune disease, selling VYVGART and VYVGART HYTRULO for conditions such as myasthenia gravis and CIDP. Its pipeline extends the same FcRn-blocking approach into other immune disorders and adds candidates aimed at inflammation and antibody-driven disease. It works with partners including Zai Lab, Halozyme and AbbVie to develop or commercialise specific molecules. Closelook's peer group places it with other scored healthcare names — Eli Lilly, Regeneron, BeiGene, UCB and Medpace among them — reflecting shared sector rather than shared disease area; the market also names Argenx's ADR line as the same company traded in New York.

Where does Argen-X sit in the AI build-out?

Argen-X carries no seat in Rubin, our AI build-out index, and sits instead in the Healthcare sector of the wider Closelook universe, where it is grouped with other scored biopharma names rather than tied to any hardware or software layer. It carries a Closelook score with momentum as the strongest module and valuation as the weakest; it holds no seat in Rubin or our other indices and has not drawn quotes in the diary's editions.

Does Argen-X pay a dividend?

No cash distribution shows in Argen-X’s price series over the last three years. The share count rose 1.3% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ARGX.BR, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.